28122459|t|Increased dissolution rates of tranilast solid dispersions extruded with inorganic excipients
28122459|a|The purpose of this study was to evaluate the performance of Neusilin ® (NEU) a synthetic magnesium aluminometasilicate as an inorganic drug carrier co-processed with the hydrophilic surfactants Labrasol and Labrafil to develop Tranilast (TLT)-based solid dispersions using continuous melt extrusion (HME) processing. Twin-screw extrusion was optimized to develop various TLT / excipient / surfactant formulations followed by continuous capsule filling in the absence of any downstream equipment. Physicochemical characterization showed the existence of TLT in partially crystalline state in the porous network of inorganic NEU for all extruded formulations. Furthermore, in-line NIR studies revealed a possible intermolecular H-bonding formation between the drug and the carrier resulting in the increase of TLT dissolution rates. The capsules containing TLT -extruded solid dispersions showed enhanced dissolution rates and compared with the marketed Rizaben (®) product.
28122459	10	21	dissolution	T061	C1285147
28122459	41	58	solid dispersions	T122	C3859614
28122459	73	82	inorganic	T077	C1881215
28122459	83	93	excipients	T122	C0015237
28122459	155	163	Neusilin	T197	C3714234
28122459	167	170	NEU	T197	C3714234
28122459	184	213	magnesium aluminometasilicate	T121,T197	C0051515
28122459	230	242	drug carrier	T122	C0013161
28122459	265	276	hydrophilic	T080	C0475370
28122459	277	288	surfactants	T120	C0038891
28122459	289	297	Labrasol	T121	C1099415
28122459	302	310	Labrafil	T120	C0038891
28122459	322	331	Tranilast	T109,T121	C0146337
28122459	333	336	TLT	T109,T121	C0146337
28122459	344	361	solid dispersions	T122	C3859614
28122459	368	393	continuous melt extrusion	T067	C1522240
28122459	395	398	HME	T067	C1522240
28122459	412	432	Twin-screw extrusion	T067	C1522240
28122459	466	469	TLT	T109,T121	C0146337
28122459	472	481	excipient	T122	C0015237
28122459	484	494	surfactant	T120	C0038891
28122459	495	507	formulations	T077	C1705957
28122459	531	538	capsule	T122	C0006935
28122459	539	546	filling	T059	C3830127
28122459	569	589	downstream equipment	T073	C0014672
28122459	591	623	Physicochemical characterization	UnknownType	C0683121
28122459	648	651	TLT	T109,T121	C0146337
28122459	655	664	partially	T081	C0728938
28122459	665	682	crystalline state	T104	C0444626
28122459	708	721	inorganic NEU	T197	C3714234
28122459	739	751	formulations	T077	C1705957
28122459	766	785	in-line NIR studies	T059	C0376519
28122459	806	830	intermolecular H-bonding	T070	C0020276
28122459	853	857	drug	T121	C1254351
28122459	866	873	carrier	T122	C0013161
28122459	903	906	TLT	T109,T121	C0146337
28122459	907	918	dissolution	T061	C1285147
28122459	930	938	capsules	T122	C0006935
28122459	950	953	TLT	T109,T121	C0146337
28122459	964	981	solid dispersions	T122	C3859614
28122459	998	1009	dissolution	T061	C1285147
28122459	1047	1054	Rizaben	T121	C0282555